8:30-8:50
Opening and inaugural lecture
8:30 -8:35
Opening - Robert Flisiak (Białystok, Poland)
8:35 -8:50
HBV meets the musical genius. Can it inspire novel research in hepatitis B patients? - Piotr Rzymski (Poznań, Poland)
8:50-9:50
Steatotic liver disease - renamed disease - Krzysztof Simon, Jan Sperl
8:50 - 9:05
Alcohol associsted liver disease spectrum - our right and left turns - Lubomir Skladany (Banska Bystrica, Slovakia)
9:05 - 9:20
Impact of non-alcoholic fatty liver disease on clinical outcomes in patients with Covid-19 - Adriana Vince (Zagreb, Croatia)
9:20 - 9:35
Association of sarcopenia and NAFLD - Ivana Mikolasevic (Rijeka, Croatia)
9:50 - 10:50
Gut and the liver - Michał Kukla, Ivica Grgurevic
9:50 - 10:05
Gut metagenome analysis in severe alcohol associated hepatitis: a cohort study - Katarina Soltys (Bratislava, Slovakia), Lubomir Skladany (Banska Bystrica, Slovakia)
10:05 - 10:20
Circulating microbiome in patients with liver cirrhosis - Rolandas Gedgaudas (Kaunas, Lithuania)
10:20 - 10:35
Fecal calprotectin levels in decompensated advanced chronic liver diseases, do we need to measure? - Tomas Koller (Bratislava, Slovakia)
10:50 - 11:05
Coffee break
11:05 - 12:50
Viral hepatitis - Małgorzata Pawłowska, Adriana Vince
11:05 - 11:20
The most difficult to cure with pangenotypic regimens HCV infected population - Robert Flisiak (Białystok, Poland)
11:20 - 11:35
Does a positive HCV RNA result at the end of DAA therapy herald the ineffectiveness of the treatment? - Dorota Zarębska-Michaluk (Kielce, Poland)
11:35 - 11:50
A model for detection and linkage to care of HCV infected persons in Croatian prisons - Lucija Virovic Jukic (Zagreb, Croatia)
11:50 - 12:05
Hepatitis C screening and elimination program in Lithuania: the first year results - Limas Kupčinskas (Kaunas, Lithuania)
12:05 - 12:20
The significance of hepatitis delta in Central Europe - Jerzy Jaroszewicz (Bytom, Poland)
12:20 - 12:35
Epidemiology of hepatitis E in Croatia - Anna Mrzljak (Zagreb, Croatia)
12:50 - 14:05
Liver transplantation and hepatic surgery - Piotr Małkowski, Pavel Trunecka
12:50 - 13:05
How do we prepare cirrhotic patients to surgery? - Michał Kukla (Kraków, Poland)
13:05 - 13:20
Liver transplantation in primary sclerosing cholangitis - can we do better? - Tajana Filipec Kanizaj (Zagreb, Croatia)
13:20 - 13:35
Porphyrias as an indication for liver transplantation - Jan Sperl (Prague, Czech Rep.)
13:35 - 13:50
Fatty liver disease after liver transplantation - Pavel Trunecka (Prague, Czech Rep.)
15:00-16:15
Hepatocellular carcinoma - Jerzy Jaroszewicz, Bela Hunyady
15:00-15:15
Subclinical inflammation predicts prognosis in hepatocellular cancer - Peter Jarcuska (Kosice, Slovakia)
15:15-15:30
Time for personalised screening of HCC? - Sona Frankova (Prague, Czech Rep.)
15:30-15:45
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models - Piotr Małkowski (Warszawa, Poland)
15:45-16:00
Chemerine and betatrofine level in patients with HCC-diagnostic value - Monika Pazgan-Simon, Joanna Górka-Dynysiewicz, Krzysztof Simon (Wrocław, Poland)
16:15-16:30
Coffree break
16:30-18:00
Diagnostic and therapeutic issues related to chronic liver diseases - Dorota Zarębska-Michaluk, Peter Jarcuska
16:30 - 16:45
Cases of acute or acute-on-chronic liver failure - Bela Hunyady (Pecs, Hungary)
16:45 - 17:00
Biomarkers of portal hypertension in compensated advanced chronic liver disease - Ivica Grgurevic (Zagreb, Croatia)
17:00 - 17:15
Do we need second line treatment in primary biliary cholangitis? - Sylvia Drazilova (Kosice, Slovakia)
17:15 - 17:30
Hepatic alveolar echinococcosis in Poland - current problems of epidemiology, diagnosis and treatment - Katarzyna Sikorska (Gdynia, Poland)
17:30 - 17:45
Cigarette smoking and liver fibrosis - Gabriella Par (Pecs, Hungary)
18:00
Summary and end of the conference - Robert Flisiak (Białystok, Poland)